Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Tesamorelin
FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.
Tier Alow risk
02· Subject
Semaglutide
FDA-approved GLP-1 receptor agonist with strong human data for diabetes and obesity management.
Tier Amedium risk
01 · At a glance
| Decision factor | Tesamorelin | Semaglutide | Tirzepatide |
|---|---|---|---|
| Primary fit | fat loss & metabolism and gh axis optimization comparisons | fat loss & metabolism research where you want a clear starting point | fat loss & metabolism research where you want a clear starting point |
| Evidence | Tier A | Tier A | Tier A |
| Risk | low | medium | medium |
| Experience level | advanced | intermediate | intermediate |
| Budget tier | premium | premium | premium |
| Administration route | subcutaneous | subcutaneous, oral | subcutaneous |
02 · Use case & timing
| Decision factor | Tesamorelin | Semaglutide | Tirzepatide |
|---|---|---|---|
| Goal fit | Fat Loss & Metabolism, GH Axis Optimization | Fat Loss & Metabolism | Fat Loss & Metabolism |
| What users compare it for | Visceral fat reduction in HIV lipodystrophy (evidence-backed). General weight loss claims are limited. | Clinically meaningful appetite reduction, HbA1c improvement, and substantial body-weight reduction in approved-use populations. | Large reductions in HbA1c and body weight in approved-use populations, with reduced appetite and improved metabolic markers. |
| Onset timeline | Clinical endpoints assessed at 26 weeks in pivotal studies. | Glucose effects emerge over the first weeks; weight-loss effects build across 3 to 12 months. | Metabolic effects begin within weeks; major body-composition changes accrue over months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Tesamorelin | Semaglutide | Tirzepatide |
|---|---|---|---|
| Adverse effects | Increased neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance/diabetes, hypersensitivity. | Common GI adverse effects include nausea, vomiting, diarrhea, and constipation. Gallbladder and pancreatitis concerns exist, and thyroid C-cell tumor warning remains part of class labeling. | GI intolerance is most common: nausea, vomiting, diarrhea, constipation, and appetite suppression. Gallbladder and pancreatitis concerns remain relevant. |
| Contraindications | Active malignancy, pregnancy, pituitary gland disorders (per label). | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, severe gastroparesis, pregnancy, and concurrent insulin/sulfonylureas. | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, pregnancy, and other glucose-lowering drugs. |
| Interaction notes | CYP450-metabolized drugs; glucocorticoid replacement requirements may be affected. | Additive hypoglycemia risk with insulin or sulfonylureas. Delayed gastric emptying can alter absorption timing for oral drugs. | Additive hypoglycemia risk with insulin or secretagogues. Delayed gastric emptying can affect oral-drug absorption timing. |
| Regulatory status | Prescription-approved | Prescription-approved | Prescription-approved |
| FDA flag | No current flag noted | FDA compounding caution | FDA compounding caution |
| WADA status | WADA S2 | Not listed | Not listed |
04 · Age & monitoring
| Decision factor | Tesamorelin | Semaglutide | Tirzepatide |
|---|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64, 65+ | 25-34, 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Not yet documented | Strongest fit for adults where weight, glucose control, and cardiometabolic risk are part of the decision. | Most relevant in adult metabolic-health and obesity contexts rather than early-life performance use. |
| Monitoring burden | Not specified | medium | medium |
| Follow-up cadence | Not yet documented | Early tolerance review in the first weeks, then metabolic follow-up every few months. | Early tolerance review, then periodic metabolic follow-up every few months. |
05 · Cost & sourcing
| Decision factor | Tesamorelin | Semaglutide | Tirzepatide |
|---|---|---|---|
| Typical cycle cost | $600.00 | $120.00 | $200.00 |
| Estimated monthly cost | $600.00 | $120.00 | $200.00 |
| Cost confidence | High confidence | High confidence | Moderate confidence |
06 · Before you buy
| Decision factor | Tesamorelin | Semaglutide | Tirzepatide |
|---|---|---|---|
| Tracked vendor listings | 3 listings | 1 listing | 1 listing |
| Sourcing note | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Better as a standalone decision | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.